Preussner S, Frick G, Rudolph W
Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(1):37-52.
The results in the antihuman lymphocytic globulines (AHLG) therapy of 25 patients with predominantly haematological and neurological diseases are reported. Extent and scope of the side-effects observed are discussed. A careful clinical, clinico-chemical and immunological observation of the patients during the AHLG therapy is indispensable for performing this biological immunosuppression and a strict selection of patients is also required. Under these conditions there are no higher risk and responsibility in an AHLG therapy than in other intensive kinds of therapy.